Safety through 30 days postvaccination with PCV-13
| Event, n (%) | UPA 15 mg QD (N=87) | UPA 30 mg QD (N=24) |
| Any AE | 15 (17.2) | 3 (12.5) |
| AEs occurring in >1 patient | ||
| Fever | 2 (2.3) | 0 |
| Nasopharyngitis | 3 (3.4) | 0 |
| Onychomycosis | 2 (2.3) | 0 |
| Upper respiratory tract infection | 1 (1.1) | 1 (4.2) |
| Serious AE | 0 | 0 |
| AE leading to discontinuation of study drug | 0 | 0 |
| AE with reasonable possibility of being related to UPA* | 1 (1.1) | 1 (4.2) |
| Death | 0 | 0 |
*As assessed by the investigator.
AE, adverse event; PCV-13, pneumococcal 13-valent conjugate vaccine (Diphtheria CRM197 Protein); QD, once daily; UPA, upadacitinib.